In-house with Bayer: ‘Focus on quality early and stay close to inventors’

After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

AI is transforming top 100 innovators, shows index

Novartis win blocks generics relitigating $7.8bn heart drug patent

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

Cadwalader global head among trio moving to Orrick

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Senior four-partner team leaves A&O Shearman

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

More on this story

Editor's picks

Editor's picks

More features